Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LB Pharmaceuticals Inc Common Stock (LBRX)
USD31.97
-0.05 (-0.17%)
US NASDAQ Healthcare Biotechnology
Address
One Pennsylvania Plaza 10119
New York, NY, US
New York, NY, US
CEO
Heather D. Turner
Website
lbpharma.us
IPO
2025-09-11
CIK 1691082 ISIN US50180M1080
Description
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD31.97
-0.05 (-0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
264.3K
Beta
0.56
Float Shares
20.76M
Free Float %
72.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.60% | -0.99% | -11.79% | +16.49% | +57.22% | +25.65% | +61.68% | +61.68% | +61.68% | +61.68% | +61.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
31.97
Low
36.00
+12.6%
Consensus
39.50
+23.6%
Median
38.50
+20.4%
High
45.00
+40.8%
DCF (Unlevered)
9.67
-69.7%
DCF (Levered)
9.75
-69.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
37.00
+15.7%
|
| Last Quarter | 4 |
39.50
+23.6%
|
| Last Year | 8 |
35.63
+11.5%
|
| All Time | 8 |
35.63
+11.5%
|
Quality scores
Altman Z-Score
32.71
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+94.4% ★ Q1'26: +96.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-314.6% Q1'26: -535.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+614.8% Q1'26: +11,116.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.12× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 5 EPS Ana. |
Dec 2027 5 EPS Ana. |
Dec 2028 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
—
— – —
|
55.63M
55.63M – 55.63M
|
187.46M
187.46M – 187.46M
+237.0% YoY
|
| EBITDA |
-30.08M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-30.40M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-25.21M
est: -118.83M (+78.8%)
|
-87.62M
-93.13M – -82.12M
+26.3% YoY
|
-112.47M
-133.96M – -90.99M
-28.4% YoY
|
-103.04M
-129.20M – -76.87M
+8.4% YoY
|
-127.09M
-127.09M – -127.09M
-23.3% YoY
|
-98.58M
-98.58M – -98.58M
+22.4% YoY
|
| SGA |
13.66M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.00
est: -4.03 (+75.2%)
|
-3.52
-3.68 – -3.25
+12.5% YoY
|
-4.39
-5.29 – -3.60
-24.5% YoY
|
-4.12
-5.11 – -3.04
+6.0% YoY
|
-5.02
-5.02 – -5.02
-21.8% YoY
|
-3.90
-3.90 – -3.90
+22.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
77
Total invested
692.42M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
77
+10 vs prev Q
New positions
21
Closed positions
11
Increased
51
Reduced
14
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.40M +1.4M (+100.0%) | 31.07B +31.1B (+100.0%) | 5.52% +5.516 pp | 7.68% +7.676 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 2 | DEEP TRACK CAPITAL, LP | 3.35M +— (+0.0%) | 74.63M +21.7M (+41.0%) | 13.25% +0.000 pp | 1.33% -0.147 pp | USD15.79 +41.0% | 2 qtrs — |
| 3 | BLACKROCK, INC. | 2.24M +1.3M (+129.6%) | 49.84M +34.4M (+223.7%) | 8.85% +4.996 pp | 0.00% +0.001 pp | USD19.44 +14.5% | 2 qtrs — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 2.21M +431.6K (+24.3%) | 49.16M +21.1M (+75.2%) | 8.73% +1.706 pp | 0.50% +0.158 pp | USD17.05 +30.6% | 2 qtrs — |
| 5 | TCG CROSSOVER MANAGEMENT, LLC | 1.75M -1.0 (0.0%) | 38.84M +11.3M (+41.0%) | 6.90% +0.000 pp | 1.29% -0.070 pp | USD15.79 +41.0% | 2 qtrs — |
| 6 | JPMORGAN CHASE & CO | 1.61M +578.9K (+56.1%) | 35.87M +19.6M (+120.0%) | 6.37% +2.288 pp | 0.00% +0.001 pp | USD18.11 +22.9% | 2 qtrs — |
| 7 | COMMODORE CAPITAL LP | 1.50M +— (+0.0%) | 33.39M +9.7M (+41.0%) | 5.93% +0.000 pp | 2.22% +1.066 pp | USD15.79 +41.0% | 2 qtrs — |
| 8 | LOGOS GLOBAL MANAGEMENT LP | 1.20M +70.0K (+6.2%) | 26.71M +8.9M (+49.7%) | 4.74% +0.277 pp | 1.61% +0.015 pp | USD16.17 +37.7% | 2 qtrs — |
| 9 | VANGUARD GROUP INC | 1.11M +1.1M (+100.0%) | 24.77M +24.8M (+100.0%) | 4.40% +4.399 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 896.8K -71.5K (-7.4%) | 19.96M +4.7M (+30.6%) | 3.54% -0.283 pp | 0.03% +0.006 pp | USD15.79 +41.0% | 2 qtrs — |
| 11 | JENNISON ASSOCIATES LLC | 821.9K +82.8K (+11.2%) | 18.29M +6.6M (+56.8%) | 3.25% +0.327 pp | 0.01% +0.004 pp | USD16.44 +35.4% | 2 qtrs — |
| 12 | VIVO CAPITAL, LLC | 800.0K +— (+0.0%) | 17.81M +5.2M (+41.0%) | 3.16% +0.000 pp | 1.15% +0.135 pp | USD15.79 +41.0% | 2 qtrs — |
| 13 | NANTAHALA CAPITAL MANAGEMENT, LLC | 675.0K +— (+0.0%) | 15.03M +4.4M (+41.0%) | 2.67% +0.000 pp | 0.50% +0.127 pp | USD15.79 +41.0% | 2 qtrs — |
| 14 | ALYESKA INVESTMENT GROUP, L.P. | 675.0K +— (+0.0%) | 15.03M +4.4M (+41.0%) | 2.67% +0.000 pp | 0.04% +0.010 pp | USD15.79 +41.0% | 2 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 441.5K +427.9K (+3,148.1%) | 9.83M +9.6M (+4,480.5%) | 1.74% +1.691 pp | 0.00% +0.001 pp | USD22.06 +0.9% | 2 qtrs — |
| 16 | CITADEL ADVISORS LLC | 407.7K -131.7K (-24.4%) | 9.07M +558.0K (+6.6%) | 1.61% -0.521 pp | 0.00% +0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 303.1K -40.4K (-11.8%) | 6.75M +1.3M (+24.4%) | 1.20% -0.160 pp | 0.00% +0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 18 | NAN FUNG GROUP HOLDINGS LTD | 300.0K +— (+0.0%) | 6.68M +1.9M (+41.0%) | 1.19% +0.000 pp | 5.98% -1.969 pp | USD15.79 +41.0% | 2 qtrs — |
| 19 | STATE STREET CORP | 250.0K +250.0K (+100.0%) | 5.57M +5.6M (+100.0%) | 0.99% +0.988 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 20 | FMR LLC | 221.9K -147.2K (-39.9%) | 4.94M -889.4K (-15.3%) | 0.88% -0.582 pp | 0.00% 0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 21 | BAKER BROS. ADVISORS LP | 200.0K +— (+0.0%) | 4.45M +1.3M (+41.0%) | 0.79% +0.000 pp | 0.03% +0.003 pp | USD15.79 +41.0% | 2 qtrs — |
| 22 | AMERIPRISE FINANCIAL INC | 193.5K +116.1K (+149.9%) | 4.31M +3.1M (+252.3%) | 0.77% +0.459 pp | 0.00% +0.001 pp | USD19.67 +13.2% | 2 qtrs — |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 177.6K +177.6K (+100.0%) | 3.95M +4.0M (+100.0%) | 0.70% +0.702 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 24 | NORTHERN TRUST CORP | 144.0K +144.0K (+100.0%) | 3.20M +3.2M (+100.0%) | 0.57% +0.569 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 25 | HIGHVISTA STRATEGIES LLC | 140.1K +140.1K (+100.0%) | 3.12M +3.1M (+100.0%) | 0.55% +0.554 pp | 0.80% +0.803 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 26 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 100.0K +— (+0.0%) | 2.23M +647.0K (+41.0%) | 0.40% +0.000 pp | 0.11% +0.004 pp | USD15.79 +41.0% | 2 qtrs — |
| 27 | LONGBOW FINANCE SA | 82.3K +82.3K (+100.0%) | 1.83M +1.8M (+100.0%) | 0.33% +0.326 pp | 0.31% +0.310 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 28 | BOXER CAPITAL MANAGEMENT, LLC | 70.0K +— (+0.0%) | 1.56M +452.9K (+41.0%) | 0.28% +0.000 pp | 0.34% -0.011 pp | USD15.79 +41.0% | 2 qtrs — |
| 29 | UBS GROUP AG | 50.7K +49.7K (+4,706.9%) | 1.13M +1.1M (+6,676.8%) | 0.20% +0.196 pp | 0.00% +0.000 pp | USD22.13 +0.6% | 2 qtrs — |
| 30 | BANK OF AMERICA CORP /DE/ | 43.8K +42.1K (+2,474.0%) | 974.1K +947.2K (+3,528.7%) | 0.17% +0.166 pp | 0.00% +0.000 pp | USD22.01 +1.1% | 2 qtrs — |
| 31 | BANK OF NEW YORK MELLON CORP | 40.5K +40.5K (+100.0%) | 901.9K +901.9K (+100.0%) | 0.16% +0.160 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 32 | JANE STREET GROUP, LLC | 31.7K +1.4K (+4.6%) | 706.4K +227.2K (+47.4%) | 0.13% +0.006 pp | 0.00% +0.000 pp | USD16.07 +38.5% | 2 qtrs — |
| 33 | BARCLAYS PLC | 30.2K -624.0 (-2.0%) | 672.6K +185.6K (+38.1%) | 0.12% -0.003 pp | 0.00% +0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 34 | ACUTA CAPITAL PARTNERS, LLC | 30.0K +— (+0.0%) | 667.8K +194.1K (+41.0%) | 0.12% +0.000 pp | 0.45% -0.036 pp | USD15.79 +41.0% | 2 qtrs — |
| 35 | MORGAN STANLEY | 24.6K +15.0K (+156.5%) | 548.5K +396.8K (+261.7%) | 0.10% +0.059 pp | 0.00% +0.000 pp | USD19.74 +12.8% | 2 qtrs — |
| 36 | NUVEEN, LLC | 23.0K +23.0K (+100.0%) | 511.2K +511.2K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 37 | WELLS FARGO & COMPANY/MN | 22.3K +21.3K (+2,130.3%) | 496.5K +480.7K (+3,044.2%) | 0.09% +0.084 pp | 0.00% +0.000 pp | USD21.97 +1.3% | 2 qtrs — |
| 38 | COLONY GROUP, LLC | 20.1K +20.1K (+100.0%) | 447.3K +447.3K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 39 | NORGES BANK | 20.0K +20.0K (+100.0%) | 445.2K +445.2K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 40 | XTX TOPCO LTD | 19.1K +7.8K (+69.6%) | 425.6K +247.6K (+139.1%) | 0.08% +0.031 pp | 0.01% +0.002 pp | USD18.44 +20.7% | 2 qtrs — |
| 41 | MARSHALL WACE, LLP | 18.0K -237.5K (-93.0%) | 401.0K -3.6M (-90.1%) | 0.07% -0.939 pp | 0.00% -0.004 pp | USD15.79 +41.0% | 2 qtrs — |
| 42 | RHUMBLINE ADVISERS | 16.3K +16.3K (+100.0%) | 362.5K +362.5K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 43 | DEUTSCHE BANK AG\ | 13.3K +13.3K (+100.0%) | 296.0K +296.0K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 44 | TWO SIGMA INVESTMENTS, LP | 12.7K -780.0 (-5.8%) | 283.1K +70.0K (+32.8%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 45 | JEFFERIES FINANCIAL GROUP INC. | 12.4K -655.0 (-5.0%) | 277.0K +70.2K (+33.9%) | 0.05% -0.003 pp | 0.00% +0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 46 | METLIFE INVESTMENT MANAGEMENT, LLC | 11.1K +11.1K (+100.0%) | 247.2K +247.2K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 47 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.1K -271.6K (-96.1%) | 247.0K -4.2M (-94.5%) | 0.04% -1.073 pp | 0.00% -0.001 pp | USD15.79 +41.0% | 2 qtrs — |
| 48 | INVESCO LTD. | 11.0K +11.0K (+100.0%) | 243.9K +243.9K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 49 | SOLEUS CAPITAL MANAGEMENT, L.P. | 10.0K -390.0K (-97.5%) | 222.6K -6.1M (-96.5%) | 0.04% -1.542 pp | 0.01% -0.310 pp | USD15.79 +41.0% | 2 qtrs — |
| 50 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 9.0K +9.0K (+100.0%) | 199.6K +199.6K (+100.0%) | 0.04% +0.035 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 51 | SG AMERICAS SECURITIES, LLC | 6.4K +6.4K (+100.0%) | 143.0K +143.0K (+100.0%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 52 | FEDERATED HERMES, INC. | 5.0K -4.0K (-44.4%) | 111.3K -30.8K (-21.7%) | 0.02% -0.016 pp | 0.00% 0.000 pp | USD15.79 +41.0% | 2 qtrs — |
| 53 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 4.4K +4.4K (+100.0%) | 98.5K +98.5K (+100.0%) | 0.02% +0.018 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 54 | PERSISTENT ASSET PARTNERS LTD | 4.1K +4.1K (+100.0%) | 90.8K +90.8K (+100.0%) | 0.02% +0.016 pp | 0.04% +0.041 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 55 | BNP PARIBAS ARBITRAGE, SNC | 4.0K +4.0K (+100.0%) | 89.2K +89.2K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 56 | STRS OHIO | 3.4K +3.4K (+100.0%) | 75.7K +75.7K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 57 | LEGAL & GENERAL GROUP PLC | 1.9K +1.9K (+100.0%) | 41.8K +41.8K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 58 | AMERITAS INVESTMENT PARTNERS, INC. | 1.6K +1.6K (+100.0%) | 34.8K +34.8K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 59 | RUSSELL INVESTMENTS GROUP, LTD. | 1.5K +1.5K (+100.0%) | 33.9K +33.9K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 60 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.4K +1.4K (+100.0%) | 30.3K +30.3K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.001 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 61 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.2K +1.2K (+100.0%) | 26.4K +26.4K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 62 | ROYAL BANK OF CANADA | 767.00 +767.0 (+100.0%) | 17.0K +17.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 63 | STERLING CAPITAL MANAGEMENT LLC | 592.00 +592.0 (+100.0%) | 13.2K +13.2K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 64 | AMALGAMATED BANK | 605.00 +605.0 (+100.0%) | 13.0K +13.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 65 | CITIGROUP INC | 435.00 +435.0 (+100.0%) | 9.7K +9.7K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD22.26 +0.0% | 1 qtrs NEW |
| 66 | GAMMA INVESTING LLC | 14.00 +14.0 (+100.0%) | 312.00 +312.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD22.21 +0.2% | 1 qtrs NEW |
| 67 | QUARRY LP | — -11.0 (-100.0%) | — -174.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 68 | SQUAREPOINT OPS LLC | — -20.8K (-100.0%) | — -328.8K (-100.0%) | 0.00% -0.082 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 69 | BREVAN HOWARD CAPITAL MANAGEMENT LP | — -13.3K (-100.0%) | — -209.4K (-100.0%) | 0.00% -0.052 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 70 | QUANTESSENCE CAPITAL LLC | — -14.2K (-100.0%) | — -224.6K (-100.0%) | 0.00% -0.056 pp | 0.00% -0.071 pp | USD— | 2 qtrs SOLD |
| 71 | OXFORD ASSET MANAGEMENT LLP | — -17.8K (-100.0%) | — -280.5K (-100.0%) | 0.00% -0.070 pp | 0.00% -0.096 pp | USD— | 2 qtrs SOLD |
| 72 | MONASHEE INVESTMENT MANAGEMENT LLC | — -40.0K (-100.0%) | — -631.6K (-100.0%) | 0.00% -0.158 pp | 0.00% -0.315 pp | USD— | 2 qtrs SOLD |
| 73 | TD ASSET MANAGEMENT INC | — -36.8K (-100.0%) | — -580.8K (-100.0%) | 0.00% -0.145 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 74 | MILLENNIUM MANAGEMENT LLC | — -538.2K (-100.0%) | — -8.5M (-100.0%) | 0.00% -2.127 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 75 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | — -17.5K (-100.0%) | — -276.1K (-100.0%) | 0.00% -0.069 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 76 | ARISTEIA CAPITAL LLC | — -15.3K (-100.0%) | — -241.1K (-100.0%) | 0.00% -0.060 pp | 0.00% -0.006 pp | USD— | 2 qtrs SOLD |
| 77 | LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | — -10.6K (-100.0%) | — -168.0K (-100.0%) | 0.00% -0.042 pp | 0.00% -0.011 pp | USD— | 2 qtrs SOLD |
| 78 | WELLINGTON MANAGEMENT GROUP LLP | — -344.7K (-100.0%) | — -5.4M (-100.0%) | 0.00% -1.362 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 79 | HRT FINANCIAL LP | — -58.8K (-100.0%) | — -928.0K (-100.0%) | 0.00% -0.233 pp | 0.00% -0.003 pp | USD— | 2 qtrs SOLD |
| 80 | HUDSON BAY CAPITAL MANAGEMENT LP | — -27.1K (-100.0%) | — -427.9K (-100.0%) | 0.00% -0.107 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 81 | SILVERARC CAPITAL MANAGEMENT, LLC | — -70.0K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.277 pp | 0.00% -0.149 pp | USD— | 2 qtrs SOLD |
| 82 | ADAGE CAPITAL PARTNERS GP, L.L.C. | — -200.0K (-100.0%) | — -3.2M (-100.0%) | 0.00% -0.791 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 66 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 0.79% | 3.71M | 0.35% |
| 2 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 410.8K | 0.65% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 0.48% | 1.03M | 0.50% |
| 4 | iShares U.S. Pharmaceuticals ETF IHE | 0.18% | 2.42M | 0.38% |
| 5 | iShares Micro-Cap ETF IWC | 0.17% | 2.48M | 0.60% |
| 6 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.16% | 38.1K | 1.22% |
| 7 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.03% | 1.53M | 0.30% |
| 8 | iShares Russell 2000 Value ETF IWN | 0.02% | 3.50M | 0.24% |
| 9 | iShares Russell 2000 BuyWrite ETF IWMW | 0.02% | 13.4K | 0.39% |
| 10 | iShares Russell 2000 ETF IWM | 0.02% | 19.55M | 0.19% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
28.68M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Heather D. Turner | Chief Executive Officer & Director | 1M | female |
| Soffer | Chief Operating & Business Officer | 644.8K | male |
| Anna Eramo | Chief Medical Officer | 616.9K | — |
| Zachary Prensky | Co-founder, Advisor to the Chief Executive Officer & Director | 13.7K | male |
| Kaya Pai Panandiker | Chief Commercial Officer | — | female |
| Lindsay Beaupre | Senior VP of People & Culture | — | female |
| Marc L. Panoff | Senior Vice President of Finance | — | male |
| Minako Pazdera | General Counsel | — | female |
| Richard Silva | Senior Vice President of Technical Operations | — | — |
| James Rawls | Senior Vice President of Regulatory Affairs | — | — |
| Ellen Rose | Senior Vice President of Corporate Affairs | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LBRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
